Production of [ 89 Zr]Oxinate 4 and cell radiolabeling for human use

• Published in: Journal of labelled compounds & radiopharmaceuticals 2021-05, Vol.64 (5), p.209-216
• Main Authors: Massicano, Adriana V F, Bartels, Jennifer L, Jeffers, Charlotte D, Crenshaw, Bryant K, Houson, Hailey, Mueller, Christina, Younger, Jarred W, Knapp, Paul, McConathy, Jonathan E, Lapi, Suzanne E
• Format: Article
• Language: English
• Subjects: Humans; Isotope Labeling; Leukocytes; Radiochemistry; Radioisotopes - chemistry; Radiopharmaceuticals - chemical synthesis; Radiopharmaceuticals - chemistry; Zirconium - chemistry
• ISSN: 0362-4803; 1099-1344
• DOI: 10.1002/jlcr.3901

[ Zr]Oxinate is a Positron Emission Tomography (PET) tracer for cell radiolabeling that can enable imaging techniques to help better understand cell trafficking in various diseases. Although several groups have synthetized this compound for use in preclinical studies, there is no available data regarding the production of [ Zr]Oxinate for human use. In this report, we describe the detailed production of [ Zr]Oxinate under USP and autologous leukocyte radiolabeling under USP . The final product presented high radiochemical purity and stability at 24 h post synthesis (>99%) and passed in all quality control assays required for clinical use. [ Zr]Oxinate did not compromise the white blood cells viability and did not show considerable cellular efflux up to 3 h post labeling. The translation of this technique into human use can provide insight into several disease mechanisms since [ Zr]Oxinate has the potential to label any cell subset of interest.